Lilly and Incyte Announce Submission of …

Lilly and Incyte Announce Submission of …

… Corporation on January 19 announced that Lilly has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of oral once-daily baricitinib for the treatment of moderately-to-severely active rheumatoid

(Visited 2 times, 1 visits today)
3
Like
Save

Comments

Comments are disabled for this post.